Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

The U.S.-based NEW DAY clinical trial enrolled 306 patients with diabetic macular edema who received a single Iluvien ...

In the 36-month period immediately preceding ILUVIEN administration, patients received median 3.4 treatments per year. Thus, ILUVIEN treatment resulted in a 70.5% reduction in treatment burden.

About ILUVIEN ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye.

ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis IndicationsATLANTA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera ...

WATERTOWN, Mass.-- (BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV - News), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today ...

“From a creative standpoint, the campaign was focused on bringing light to having something like Iluvien and how that would be beneficial to their lifestyle,” Hoffman said. “If you are dealing with ...

ILUVIEN revenues should pick up by the end of the year. DME is a chronic disease and there is a desperate need for a sustained release treatment and ILUVIEN fills that need very well.